Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA) DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period) Enrollment completed with 529 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025... Read More